ATXA presented preclinical efficacy results of its lead drug candidate NTP42 for the treatment of pulmonary arterial hypertension (PAH) at the European Respiratory Society (ERS) International Congress 2022, held from September 4-6, 2022 in Barcelona, Spain.
In a presentation entitled "NTP42 alleviates experimental pulmonary arterial hypertension and promotes beneficial right ventricular adaptation, preserving right heart function", ATXA Senior Scientist Dr Eamon Mulvaney outlined some key new data on the benefits of the formulated NTP42 in preclinical disease models, including in both the monocrotaline (MCT)-induced and pulmonary artery banded (PAB) models of PAH and right ventricular (RV) dysfunction, respectively.
Data from these models demonstrate that NTP42 not only alleviates pulmonary PAH-like pathologies, but also promotes beneficial RV hypertrophy and improves cardiac function. Notably, we also revealed that expression of the thromboxane receptor, the cellular target for NTP42, is found to be is significantly upregulated within the RV in experimental models and in human clinical samples, highlighting the importance of this largely-ignored PAH target ripe for pharmaceutical intervention.
Click here to view our presentation.
The ERS Congress is a once-a-year occasion when the world’s respiratory experts come together, to present and discuss the latest scientific and clinical advances across the entire field of respiratory medicine. It welcomes a global audience of respiratory focused professionals inclusive of clinicians, scientists and researchers, and allied healthcare professionals.
ATXA's conference poster and accompanying audio commentary is also available to view on the ERS Congress Virtual Platform here (registration required).